Novartis CEO on Second-Quarter, Growth, Covid Vaccine Trial

The transcript discusses the rebound in healthcare demand post-COVID, highlighting growth in various therapeutic areas despite challenges like the Delta variant. It covers Entresto's strong market performance and Novartis' strategic focus on cutting-edge technologies, including RNA and gene therapies. The development of a COVID-19 antiviral shot is also discussed, along with Novartis' commitment to a hybrid working model for employees.

What technologies is Novartis focusing on for future growth?

What is the company's approach to hybrid working for employees?